CN109136200A - A kind of recombination infectious hematopoietic necrosis poison and its construction method and application - Google Patents

A kind of recombination infectious hematopoietic necrosis poison and its construction method and application Download PDF

Info

Publication number
CN109136200A
CN109136200A CN201811100029.1A CN201811100029A CN109136200A CN 109136200 A CN109136200 A CN 109136200A CN 201811100029 A CN201811100029 A CN 201811100029A CN 109136200 A CN109136200 A CN 109136200A
Authority
CN
China
Prior art keywords
poison
gene
infectious hematopoietic
necrosis
hematopoietic necrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201811100029.1A
Other languages
Chinese (zh)
Other versions
CN109136200B (en
Inventor
赵景壮
徐黎明
卢彤岩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heilongjiang River Fisheries Research Institute of Chinese Academy of Fishery Sciences
Original Assignee
Heilongjiang River Fisheries Research Institute of Chinese Academy of Fishery Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heilongjiang River Fisheries Research Institute of Chinese Academy of Fishery Sciences filed Critical Heilongjiang River Fisheries Research Institute of Chinese Academy of Fishery Sciences
Priority to CN201811100029.1A priority Critical patent/CN109136200B/en
Publication of CN109136200A publication Critical patent/CN109136200A/en
Application granted granted Critical
Publication of CN109136200B publication Critical patent/CN109136200B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention discloses a kind of recombination infectious hematopoietic necrosis poison and its construction method and applications.For recombination infectious hematopoietic necrosis's poison provided by the present invention compared with infectious hematopoietic necrosis's poison before transformation, difference is only that the encoding gene (the VP2 gene of such as infectious pancreas necrosis virus) between the P gene and M gene in the geneome RNA of infectious hematopoietic necrosis's poison before the transformation also containing destination protein.The present invention saves the recombinant virus rIHNV-VP2 for having successfully been obtained and capable of expressing infectious pancreas necrosis virus VP2 gene using reverse genetics manipulation technology using IHNV as parental virus in vitro.The recombinant virus rIHNV-VP2 obtained constructed by the present invention, IHNV and IPNV can be played the role of while prevent and treat by demonstrating the recombinant virus by campaign, and the present invention is that the study on prevention of further development IHNV and IPNV has established solid foundation.

Description

A kind of recombination infectious hematopoietic necrosis poison and its construction method and application
Technical field
The present invention relates to field of biotechnology, and in particular to a kind of recombination infectious hematopoietic necrosis is malicious and its constructs Method and application.
Background technique
Infectious hematopoietic necrosis (Infectious hematopoietic necrosis, IHN) and infectiousness pancreas Dirty necrosis sick (Infectious pancreatic necrosis, IPN) is disease that is most common, seriously endangering salmon trout health Toxoinfection disease, is the most important two kinds of diseases for causing salmon trout industry heavy economic losses in world wide at present.It infects Property hematopoietic necrosis virus (Infectious haematopoietic necrosis virus, IHNV), belong to play shape disease Malicious section (Rhabdoviridae), Nola's Rhabdovirus (Novirhabdovirus) are sub-thread minus-stranded rna virus, virus Full-length genome is about 11kb, include six genes, be separately encoded virus nucleoprotein (N), phosphoprotein (P), stromatin (M), Glycoprotein (G), non-structural protein (NV) and polymerase protein (L).It can be by worldwide IHNV according to G-protein gene order It is divided into five kinds of genotype of U, M, L, E and J.Wherein, for U, M, L genotype Major Epidemic in North America, E genotype is popular in Europe, J base Because type is popular in Asia.According to pathogenic strain, environmental factor, the difference of the age of a fish, IHNV can cause salmon trout be up to 100% it is dead Rate is died, is the number one killer of serious obstruction salmon trout sustainable health development at present.Infectious pancreas necrosis virus (Infectious pancreatic necrosis virus, IPNV) belongs to the aquatic birnavirus of biplate section RNA virus section Belong to.IPNV genome is made of (A segment and B segment) two double-stranded RNAs, A segment overall length 3092bp, encodes 106kDa poly egg White (NH2-VP2-VP4-VP3-COOH), wherein VP2 and VP3 is two kinds of major structural proteins of the virus, and VP2 is induction protection The main immunogens of property neutralizing antibody.B segment overall length 2777bp encodes albumen pVP1 (94kDa), is that virion relies on RNA polymerase.Due to the difference of strain, host and environmental factor, IPNV can cause 10%~90% death rate.IHN and IPN master Endanger fry and the rainbow trout (Onchorhyncus mykiss) of juvenile fish stage, brook trout (Salvelinus Fontinalis), brown trout (Salmo trutta), Atlantic salmon (Salmo salar) and hemp, which breathe out, belongs to (Oncorhynchus Spp. fry and juvenile fish) are the main viral infectious of serious obstruction salmon trout sustainable health development at present.
With classics slave phenotypic alternation to the thinking of progress gene expression characteristics research on the contrary, reverse genetics manipulation technology (reverse genetics) refers to the infective molecule cloning by constructing RNA virus, in viral cDNA molecules level on pair It carries out external manual operation (such as progress point mutation, missing, insertion, transversion, indexing and complementation transformation), changes virus Certain features (virulence as lowered virus, improve the infecting potential etc. of virus), the cDNA molecule of virus is connected into expression and is carried Body, transfection cell obtain the infection clones of virus, also referred to as " virus rescue " (the rescue of virus).Pass through Reverse genetics manipulation technology can study the gene duplication of RNA virus and expression regulation mechanism, rna editing and spontaneous recombination and lure Interaction relationship, the viral resistant strategies, gene therapy research between recombination, virus and host are led, and building new virus carries Body carrys out expression alien gene and carries out the development etc. of vaccine.
Summary of the invention
The object of the present invention is to provide a kind of recombination infectious hematopoietic necrosis poison and its construction method and applications.
In a first aspect, a kind of claimed recombination infectious hematopoietic necrosis poison.
Infectious hematopoietic organ necrosis before recombination infectious hematopoietic necrosis's poison provided by the present invention and transformation Virus is compared, difference be only that P gene in the geneome RNA of infectious hematopoietic necrosis's poison before the transformation and Also containing the encoding gene of destination protein between M gene.
Recombination infectious hematopoietic necrosis's poison provided by the present invention is in infectious hematopoietic necrosis's poison (IHNV) recombinant virus obtained after the encoding gene of destination protein is inserted between the P gene in geneome RNA and M gene.
Wherein, the phosphoprotein (P) of the P gene coding infectious hematopoietic necrosis malicious (IHNV)；The M gene is compiled The stromatin (M) of code infectious hematopoietic necrosis malicious (IHNV).
Further, the encoding gene of the destination protein can be the antigen gene of target viral or the coding of labelled protein Gene.
Further, the target viral can be other viruses outside infectious hematopoietic necrosis's poison, such as infect Property pancreas necrosis virus (IPNV) etc.；Correspondingly, the antigen gene of the target viral concretely infectious pancreatic necrosis The VP2 gene etc. of malicious (IPNV).The labelled protein can be green fluorescent protein etc..
In a specific embodiment of the invention, the infectious hematopoietic necrosis before the transformation malicious (IHNV) is specific It is BLk94 plants of infectious hematopoietic necrosis's poison (IHNV-BLk94).The infectious pancreas necrosis virus (IPNV) is specific It is ChRtm213 plants of infectious pancreas necrosis virus (IPNV-ChRtm213).
Further, the P in the geneome RNA of the infectious hematopoietic necrosis before the transformation malicious (IHNV) Gene encodes phosphoprotein (P) shown in SEQ ID No.1；Infectious hematopoietic necrosis's before the transformation malicious (IHNV) Stromatin (M) shown in M gene coding SEQ ID No.2 in geneome RNA.
Corresponding to gene level, in the geneome RNA of the infectious hematopoietic necrosis malicious (IHNV) before the transformation The P gene coding region nucleotide sequence as shown in SEQ ID No.4；Infectious hematopoietic organ necrosis before the transformation The coding region nucleotide sequence of the M gene in the geneome RNA of viral (IHNV) is as shown in SEQ ID No.5.
Further, shown in the VP2 gene coding SEQ ID No.3 of the infectious pancreas necrosis virus (IPNV) VP2 albumen.
Corresponding to gene level, the nucleotide sequence such as SEQ of the VP2 gene of the infectious pancreas necrosis virus (IPNV) Shown in ID No.6.
Further, recombination infectious hematopoietic necrosis's poison and the infectious hematopoietic organ necrosis before transformation Virus is compared, and difference is only that the P gene in the geneome RNA of infectious hematopoietic necrosis's poison before the transformation A segment (" P GE-M GS " in Fig. 3 in A) between code area and the code area of the M gene is replaced for segment B (Fig. 3 " P GE-M GS-VP2gene-P GE-M GS " in middle B).Wherein, the sequence of the segment A is SEQ ID No.7；It is described The sequence of segment B is SEQ ID No.8 (i.e. SEQ ID No.7+SEQ ID No.6+SEQ ID No.7).
More specifically, the recombination infectious hematopoietic necrosis poison can be according to method described in following second aspect It prepares.
Second aspect, it is claimed a kind of to prepare recombination infectious hematopoietic organ described in first aspect above The method of necrosis virus.
Preparation provided by the present invention recombinates the side of infectious hematopoietic necrosis's poison above described in first aspect Method, it may include following steps: by the corresponding cDNA sequence of geneome RNA containing recombination infectious hematopoietic necrosis's poison The recombinant plasmid and helper plasmid cotransfection EPC cell of column, to obtain the recombination infectious hematopoietic necrosis poison.
Wherein, described " the corresponding cDNA sequence of geneome RNA containing recombination infectious hematopoietic necrosis's poison Recombinant plasmid " in the corresponding cDNA sequence of geneome RNA of starting recombination infectious hematopoietic necrosis's poison express Promoter be T7 promoter, it is described recombination infectious hematopoietic necrosis's poison the corresponding cDNA sequence of geneome RNA Coded sequence and T7 termination sequence (being denoted as pIHNV-VP2) also containing fourth hepatovirus ribozyme afterwards.The helper plasmid shares 4 It is a: N gene (the coding base of nucleoprotein N in the geneome RNA containing infectious hematopoietic necrosis's poison before the transformation Cause) the corresponding cDNA sequence in code area helper plasmid 1 (being denoted as pHelp-N)；Contain the infectious hematopoietic before the transformation The auxiliary of the corresponding cDNA sequence in code area of P gene (encoding gene of phosphoprotein P) in the geneome RNA of organ necrosis virus Plasmid 2 (is denoted as pHelp-P)；NV gene in geneome RNA containing infectious hematopoietic necrosis's poison before the transformation The helper plasmid 3 (being denoted as pHelp-Nv) of the corresponding cDNA sequence in code area of (encoding gene of non-structural protein NV)；Contain L gene (encoding gene of polymerase protein L) in the geneome RNA of infectious hematopoietic necrosis's poison before the transformation The helper plasmid 4 (being denoted as pHelp-L) of the corresponding cDNA sequence in code area.
In the method, when carrying out the cotransfection, the pIHNV-VP2, the pHelp-N, the pHelp-P, The quality proportioning of the pHelp-Nv and the pHelp-L are 2.0:1.0:0.5:0.25:0.5.
In the method, when CPE occurs in 60% or more cell, the recombination infectious hematopoietic organ necrosis is harvested Virus.
The third aspect, the biomaterial of claimed following (a1) or (a2) or (a3):
(a1) in vitro zooblast or recombinant bacterium containing previously described recombination infectious hematopoietic necrosis's poison；
(a2) carrier of geneome RNA or cDNA containing previously described recombination infectious hematopoietic necrosis's poison；
(a3) vaccine containing previously described recombination infectious hematopoietic necrosis's poison.
Since the IHNV-BLk94 virus is low virulent strain, direct injection can carry out immune effect detection, nothing after 60d is immunized Need inactivation treatment.
Fourth aspect, claimed following any application:
(b1) previously described recombination infectious hematopoietic necrosis poison or the biomaterial are used for pre- in preparation Anti- and/or treatment disease due to caused by infectious hematopoietic necrosis malicious (IHNV) and/or the infection of previously described target viral Application in the product of disease；
(b2) previously described recombination infectious hematopoietic necrosis poison or the biomaterial are being prepared for pressing down Application in the product of infectious hematopoietic necrosis processed malicious (IHNV) and/or the infection of previously described target viral；
(b3) previously described recombination infectious hematopoietic necrosis poison or the biomaterial are preventing and/or are controlling It treats due to answering in infectious hematopoietic necrosis malicious (IHNV) and/or previously described target viral infection associated diseases With；
(b4) previously described recombination infectious hematopoietic necrosis poison or the biomaterial are inhibiting infectiousness Hematopoietic necrosis virus (IHNV) and/or previously described target viral infection in application.
In a specific embodiment of the invention, the target viral is specially infectious pancreas necrosis virus (IPNV). The infectious hematopoietic necrosis malicious (IHNV) and/or infectious pancreas necrosis virus (IPNV) infection are infection rainbow trout Fish.
The present invention is saved in vitro using reverse genetics manipulation technology and is successfully obtained using IHNV strain BLk94 as parental virus RIHNV-BLk94.The Viral structural protein VP2 gene of IPNV is inserted into P and the M gene of rIHNV-BLk94 genome by the present invention Between, building has obtained recombinant virus rIHNV-VP2.Demonstrating the recombinant virus by campaign can play while preventing and treating The effect of IHNV and IPNV, the present invention are that the study on prevention of further development IHNV and IPNV has established solid foundation.
Detailed description of the invention
Fig. 1 is rIHNV-BLk94 strain full length cDNA sequence plasmid construction policy map.
Fig. 2 is the construction strategy figure of recombinant plasmid pIHNV-GFP-N/P.
Fig. 3 is interleaving for the P and M gene of the invention that the VP2 gene of IPNV strain is inserted into rIHNV-BLk94 genome Enter position view.A is rIHNV-BLk94 genome relevant range schematic diagram；B is recombinant virus rIHNV-VP2 genome phase Close area schematic.
Fig. 4 is rIHNV-VP2 strain full length cDNA sequence plasmid construction policy map.
Fig. 5 is the cDNA clones of IHNV-BLk94 whole genome sequence.H1, H2, H3 are IHNV-BLk94 full-length genome sequence Column cDNA clones product；M is DL15000DNA molecular weight standard；The amplification of pFLC-LaSota carrier for expression of eukaryon skeleton.
Fig. 6 is each recombinant plasmid PCR qualification result for expressing GFP.M is DL2000DNA molecular weight standard；pIHNV-GFP- N/P, pIHNV-GFP-P/M, pIHNV-GFP-M/G, pIHNV-GFP-G/NV, pIHNV-GFP-NV/L are respectively each recombinant plasmid PCR qualification result.
Fig. 7 is the clone of IHNV-BLk94 helper plasmid.N, P, Nv and L are IHNV-BLk94 genetic fragment；M1For DL15000DNA molecular weight standard；M2For DL2000DNA molecular weight standard.
Fig. 8 is the TCID of each recombinant virus50Detection.
Fig. 9 is the growth curve of each recombinant virus.
Figure 10 is the GFP mRNA expression of each recombinant virus.
Figure 11 is the GFP protein expression level of each recombinant virus.
Figure 12 is the cytopathy of recombinant virus rIHNV-VP2.
Figure 13 is that protective rate detects after IHNV attacks poison.
Figure 14 is that IPNV attacks virus load detection in rainbow trout body after poison.
Specific embodiment
Experimental method used in following embodiments is conventional method unless otherwise specified.
The materials, reagents and the like used in the following examples is commercially available unless otherwise specified.
The genome of infectious hematopoietic necrosis's poison BLk94 plants (IHNV-BLk94) involved in following embodiments The coding region nucleotide sequence of P gene in RNA encodes phosphoprotein shown in SEQ ID No.1 as shown in SEQ ID No.4 (P).The nucleotide sequence of the code area of M gene in the geneome RNA of IHNV-BLk94 is compiled as shown in SEQ ID No.5 Stromatin (M) shown in code SEQ ID No.2.It is located at the code area of the P gene in the geneome RNA of IHNV-BLk94 The sequence such as SEQ ID of RNA segment (" P GE-M GS " in corresponding diagram 3 in A) between the code area of the M gene Shown in No.7.
The VP2 of infectious pancreas necrosis virus ChRtm213 plants (IPNV-ChRtm213) involved in following embodiments The nucleotide sequence of the code area of gene encodes VP2 albumen shown in SEQ ID No.3 as shown in SEQ ID No.6.
The building and application of embodiment 1, recombinant virus rIHNV-VP2
One, materials and methods BLk94
(1) experimental material and reagent
Trizol is Invitrogen company (10296028) product；(the letter of BLk94 plants of infectious hematopoietic necrosis's poison Claim IHNV-BLk94) (Genbank accession number: DQ164100) and ChRtm213 plants of (abbreviation IPNV- of infectious pancreas necrosis virus ChRtm213) (Genbank accession number: KX234591) is saved by this laboratory；EPC cell ATCC CRL-2872；Contain fourth liver Carrier pFLC-LaSota is transformed in the pBluescript II SK of virus ribozymal, and helper plasmid carrier pTM-NP is protected by this laboratory Deposit (bibliography " foundation of the novel recombinant Newcastle disease virus of Zhang Zhenyu (NDV) expression system and best exogenous gene expression position The Heilungkiang determination [D] set: Northeast Agricultural University, 2015:16-19. ").Cell culture fluid MEM, trypsase, Hank ' s liquid For Hyclone biotech firm product.Fetal calf serum is Gibco biotech firm product.RT-PCR one-step method kit (12574035), liposome 2000 is Invitrogen biotech firm product.In-Fusion PCR Cloning Kit kit For Clontech company (600670) product.Anti- IHNV antibody is prepared by this laboratory and is saved, which is the IHNV disease of expression The surface glycoprotein of poison is immunogene, and (bibliography is " Zhao Jingzhuan, Xu to the polyclonal antibody that immune new zealand white rabbit obtains Dawn, Liu Miao wait the truncation expression of the fishes infectious Hematopoietic Necrosis's disease viral glycoprotein of and immunogenicity detection [J] thin Born of the same parents and molecular immunology magazine, 2014,30 (12): 1238-1242. "), fluorescent marker secondary antibody is that Ebioscience biology is public Department.
(2) design of primers and synthesis
According to IHNV-BLk94 whole genome sequence and pFLC-LaSota carrier for expression of eukaryon frame sequence, Prime is utilized 5.0 software design specific primer of primer, for constructing the true of recombinant virus rIHNV-BLk94 full-length genome cDNA sequence Consideration convey records plasmid, and primer sequence is as shown in table 1.
1 rIHNV-BLk94 full-length genome cDNA sequence cloning primer of table
Primer Sequence (5 ' → 3 ')
IH1-F 5’-CGACTCACTATAGGGGTATAAAAAAAGTAACTTGACTA-3’
IH1-R 5’-AATCCAATCATACAGGCCCGATGCAGT-3’
IH2-F 5’-CTGTATGATTGGATTCTGTGGGGGGCAGTGGATAC-3’
IH2-R 5’-ACTTTGTTGTTGACGCGCTCT-3’
IH3-F 5’-TGTCAACAACAAAGTCGGGGTGCATCTCTTT-3’
IH3-R 5’-GGGACCATGCCGGCCGTATAAAAAAAGTAACAGAGAGA-3’
pB-F 5’-GGCCGGCATGGTCCCAGCCTCCTCG-3’
pB-R 5’-CCCTATAGTGAGTCGTATTAGCGGC-3’
It is soft using Prime primer 5.0 according to IHNV-BLk94 whole genome sequence and helper plasmid carrier pTM-NP Part designs specific primer, is respectively used to building recombinant virus rIHNV-BLk94 nucleoprotein (N), phosphoprotein (P), non-structural protein The eukaryon helper plasmid of white (NV) and polymerase protein (L) cDNA sequence, primer sequence are as shown in table 2.
2 rIHNV-BLk94 helper plasmid cDNA sequence cloning primer of table
According to IHNV-BLk94 whole genome sequence and GFP gene order, 5.0 software design of Prime primer is utilized Specific primer, for constructing rIHNV-BLk94 carrier expression GFP recombinant plasmid, primer sequence is as shown in table 3.
Table 3 constructs rIHNV-BLk94 carrier and expresses GFP plasmid cloning primer
According to the VP2 gene order of IPNV strain, it is used for using 5.0 software design specific primer of Prime primer It is as shown in table 4 to construct rIHNV-VP2 carrier expression VP2 recombinant plasmid primer sequence.
Table 4 constructs rIHNV-VP2 recombinant plasmid clone primer
Primer Sequence (5 ' → 3 ')
ZT-F 5’-ATGTCCATTTTCAAGAGAGCAAAGA-3’
ZT-R 5’-GCTCTCGTTTGAACTGACTCTTGGACTT-3’
VP2-F 5’-AGTTCAAACGAGAGCATGAACACATCCAAGGCAACCGCAA-3’
VP2-R 5’-CTTGAAAATGGACATTCATGCCTTTGAGGTTGGTAGGTCA-3’
(3) viral amplification and RNA are extracted
The viral suspension of IHNV-BLk94 and IPNV-ChRtm213 is used into the cell maintenance medium (MEM containing 2%FBS respectively Culture medium) dilution 105Times, it is inoculated in the EPC cell that single layer converges, is cultivated in 15 DEG C.When cytopathy occurs in 80% or more cell Become (cytopathic effect, CPE) when, collect cell culture fluid (i.e. viral suspension), take 250 μ L viral suspensions (adjust to Contain 105Virion) in the centrifuge tube of no RNA enzyme.12 000g are centrifuged 5min, removal precipitating.750 μ L Trizol are added Lysate concussion mixes, and 200 μ L phenol chloroforms are added and mix, and 12 000g are centrifuged 15min after 10min, and Aspirate supernatant is added to newly Centrifuge tube in, isometric isopropanol is added, is mixed by inversion repeatedly, 12 000g be centrifuged 15min, abandon to the greatest extent supernatant, be added 75% Ethyl alcohol 1mL, overturn washing, 12 000g be centrifuged 10min, abandon to the greatest extent supernatant, 4000 centrifugation 10s, blot the liquid of tube bottom, room temperature Dry 3min；Be added 100 μ L without RNA enzyme water, RNA precipitate is completely dissolved, be sub-packed in -80 DEG C it is spare.
(4) building of rIHNV-BLk94 strain full length cDNA sequence plasmid and eukaryon helper plasmid
1, the building of rIHNV-BLk94 strain full length cDNA sequence plasmid
The construction strategy of rIHNV-BLk94 strain full length cDNA sequence plasmid is as shown in Figure 1.
The IHNV-BLk94RNA extracted using step (3) is primer as the sequence of template, table 1, anti-using mono- step of RT-PCR Kit amplification is answered to cover IH1, IH2, IH3 segment of IHNV-BLk94 strain full-length genome.It expands IH1 segment and uses primer IH1-F and IH1-R；It expands IH2 segment and uses primer I H2-F and IH2-R；It expands IH3 segment and uses primer I H3-F and IH3-R. Then, according to Pfu UltraTMII Fusion HS archaeal dna polymerase specification, the pFLC-LaSota eukaryon saved with laboratory Expression vector is template, and the sequence (pB-F and pB-R) using table 1 is primer, expands pFLC-LaSota carrier for expression of eukaryon bone Frame segment.Object above genetic fragment is recycled using plastic recovery kit, is said according to In-Fusion PCR Cloning Kit Bright book connects IH1, IH2, IH3 and pFLC-LaSota carrier for expression of eukaryon skeleton segment, constructs containing rIHNV-BLk94 poison The plasmid pIHNV-BLk94 of strain full length cDNA sequence, and it is correct through sequence verification.
2, the building of eukaryon helper plasmid
The IHNV-BLk94RNA extracted using step (3) is primer as the sequence of template, table 2, anti-using mono- step of RT-PCR Kit is answered to expand IHNV-BLk94 strain N, P, NV and L genetic fragment respectively.Expand N genetic fragment using primer I HN-F and IHN-R；It expands P genetic fragment and uses primer I HP-F and IHP-R；It expands NV genetic fragment and uses primer I HNv-F and IHNv-R； It expands L genetic fragment and uses primer I HL-F and IHL-R.According to Pfu UltraTMII Fusion HS archaeal dna polymerase specification, For the helper plasmid carrier pTM-NP saved using laboratory as template, the sequence (phelp-F and phelp-R) using table 2 is primer, Expand helper plasmid carrier pTM-NP skeleton segment.Object above genetic fragment is recycled using plastic recovery kit, according to In- Fusion PCR Cloning Kit specification is respectively by N, P, NV and L genetic fragment and helper plasmid carrier pTM-NP matrix tablet Section connection, constructs Revive virus helper plasmid pHelp-N, pHelp-P, pHelp-Nv and pHelp-L.And through sequence verification Correctly.
(5) building of GFP subclone
Using the pIHNV-BLk94 full-length cDNA constructed in step 41 as template, NF and NR in table 3 are primer, by IHNV N gene and M gene between sequence be cloned into pcDNA3.1 carrier, obtain IHNV P gene subclone pcDNA3.1-NM/ P+。
It will be template using p519gfp plasmid (ATCC:87452), the GFP insert F and GFP insert R in table 3 For primer, amplification obtains GFP segment；Utilize pcDNA3.1-NM/P+For template, the GFP Vet F and GFP Vet R in table 3 is Primer, amplification obtain the carrier segments pcDNA3.1-NM/P of removal P gene open reading frame-；By GFP segment and pcDNA3.1- NM/P-Carrier connection after, obtain include Gene end-Gene start-GFP GFP subclone (GFP template), and It is correct through sequence verification, it is convenient to the building of later period recombinant plasmid.
(6) recombinant plasmid pIHNV-GFP-N/P, pIHNV-GFP-P/M, pIHNV-GFP-M/G, pIHNV-GFP-G/NV, The building of pIHNV-GFP-NV/L and the rescue of virus
In order to determine the optimum position of IHNV expression alien gene, indicator protein GFP is successively inserted by the present invention Between N the and P gene of IHNV genome, between P and M, between M and G, between G and NV and between NV and L, a system is constructed Arrange the different pIHNV-GFP plasmid in insertion position.
Below by taking external source GFP gene is inserted between N and P gene as an example, be described in detail the building of serial recombinant plasmid with Rescue strategy, specific strategy are as shown in Figure 2.
1, the building of recombinant plasmid pIHNV-GFP-N/P
PIHNV-BLk94 plasmid obtained in the GFP template and step 41 obtained respectively using step 5 as template, Utilize the primer amplification GFP N/P segment and pIHNV-GFP-N/P Vet segment in table 3.It is used when expanding GFP N/P segment Primer is N/P insert F and N/P insert R；The primer used when expanding pIHNV-GFP-N/P Vet segment is N/P Vet F and N/P Vet R.The segment that PCR is obtained is attached after glue recycles respectively, connection product converts bacillus coli DH 5 alpha Competent cell, picking single bacterium colony identify that correct positive plasmid is named as pIHNV-GFP-N/P plasmid (and through sequence verification Correctly).
2, the rescue of recombinant virus rIHNV-GFP-N/P
Take 2.0 μ g of pIHNV-GFP-N/P plasmid, 1.0 μ g of helper plasmid pHelp-N, 0.5 pHelp-P μ g, pHelp-Nv 0.25 0.5 μ g cotransfection EPC cell of μ g and pHelp-L, concrete operation method is according to Invitrogen company 2000 transfection procedure specification of Lipofectamine carries out.Cell after transfection is placed in 15 DEG C of incubator cultures, is seen daily Cell state is examined, when CPE occurs in 60% or more cell, harvest viral suspension is placed in -80 DEG C of packing and saves backup.
3, recombinant plasmid pIHNV-GFP-P/M, pIHNV-GFP-M/G, pIHNV-GFP-G/NV, pIHNV-GFP-NV/L Building and the rescue of virus
The structure of recombinant plasmid pIHNV-GFP-P/M, pIHNV-GFP-M/G, pIHNV-GFP-G/NV, pIHNV-GFP-NV/L Build with the rescue of virus when in addition to GFP Insert Fragment and vector amplification that the primer is different, other steps are and pIHNV- The building of GFP-N/P and virus rescue are identical.The primer used when expanding GFP P/M segment is the P/M insert F in table 3 With P/M insert R, the primer used when expanding pIHNV-GFP-P/M Vet segment is P/M the Vet F and P/M in table 3 Vet R；The primer used when expanding GFP M/G segment is M/G insert F and M/G the insert R in table 3, amplification The primer used when pIHNV-GFP-M/G Vet segment is the M/G Vet F and M/G Vet R in table 3；Expand GFP G/NV piece The primer used when section expands pIHNV-GFP-G/NV Vet piece for G/NV insert F and G/NV the insert R in table 3 The primer used when section is the G/NV Vet F and G/NV Vet R in table 3；When expanding GFP NV/L segment the primer that uses for NV/L insert F and NV/L insert R in table 3, when expanding pIHNV-GFP-NV/L Vet segment the primer that uses for NV/L Vet F and NV/L Vet R in table 3.
(7) Revive virus rIHNV-GFP-N/P, rIHNV-GFP-P/M, rIHNV-GFP-M/G, rIHNV-GFP-G/NV And the TCID of rIHNV-GFP-NV/L50Measurement
The good EPC cell of growth conditions is taken, according to 2 × 10 after digestion4A/100 μ L are sub-packed in 96 orifice plates, are inoculated with each point Viral suspension from strain difference dilution, each 8 hole of dilution, every 100 μ L of hole set up blank control group simultaneously, and 15 DEG C are cultivated, After observation 7 days, TCID is calculated using Reed-Muench method50。
(8) Revive virus rIHNV-GFP-N/P, rIHNV-GFP-P/M, rIHNV-GFP-M/G, rIHNV-GFP-G/NV And the growth curve of rIHNV-GFP-NV/L
The good EPC cell of growth conditions is taken, according to 2 × 10 after digestion4A/100 μ L are sub-packed in 96 orifice plates, are inoculated with each point Viral suspension from strain difference dilution, each 8 hole of dilution, every 100 μ L of hole set up blank control group simultaneously, and 15 DEG C are cultivated, Every 12h collects primary virus, calculates TCID using Reed-Muench method50Draw viral growth curves.
(9) transcriptional level detection Revive virus rIHNV-GFP-N/P, rIHNV-GFP-P/M, rIHNV-GFP-M/G, The expression quantity of rIHNV-GFP-G/NV and rIHNV-GFP-NV/L GFP mRNA
Inoculation EPC cell monolayer in be changed in 6 porocyte culture plates, before virus inoculation containing 10% serum MEM training Support base.It is inoculated with each Revive virus respectively in 6 orifice plates with 0.1MOI (Multiplicity of infection), 15 DEG C are cultivated The maintaining liquid of 2% serum is changed to after 1h.15 DEG C, 0.5%CO2Under the conditions of cultivate 48h after extract viral RNA, utilize One Step SYBR PrimeScript PLUS RT-PCR Kit (RR096A, Takara, Japan) is to recombinant virus GFP mRNA Expression quantity detected, the detection primer used is RT-GFP F:5 '-CGAGGTGGTGTACATGAACGA-3 ', RT-GFP R:5 '-GCTGTAGAACTTGCCGCTGTT-3 ', reference gene are the N protein gene of virus, and internal control primer is RT-N F:5 '- AGGAGAGGGAACGAGAAGG-3 ', RT-N R:5 '-TGTTGGGATCTGCGAAAGTG-3 '.
(10) recombinant virus rIHNV-GFP-N/P, rIHNV-GFP-P/M, rIHNV-GFP-M/G, rIHNV-GFP-G/NV And the detection of rIHNV-GFP-NV/L GFP expressing quantity
Inoculation EPC cell monolayer in be changed in 6 porocyte culture plates, before virus inoculation containing 10% serum MEM training Support base.It is inoculated with each Revive virus respectively in 6 orifice plates with 0.1MOI (Multiplicity of infection), 15 DEG C are cultivated The maintaining liquid of 2% serum is changed to after 1h.15 DEG C, 0.5%CO2Under the conditions of cultivate 48h after in using pancreatin will be under cell dissociation Come, PBS utilizes the expression of each recombinant virus green fluorescent protein GFP of flow cytomery after washing 2 times.
(11) rIHNV-VP2 strain full length cDNA sequence plasmid construction
Early-stage study result demonstrates IHNV mRNA transcription amount and successively successively decreases according to the sequence of genome 3 ' to 5 ', and Compared with other insertion points, when between P the and M gene that GFP is inserted into rIHNV-BLk94 carrier, the expression quantity of GFP albumen Highest.This explanation, the transcription properties and foreign gene for comprehensively considering IHNV genome mRNA on influence caused by virus replication, Noncoding region between rIHNV-BLk94 genome P and M gene is the optimum position of expression alien gene.Therefore the present invention will The VP2 gene of IPNV strain is inserted between P the and M gene of rIHNV-BLk94 genome, is constructed containing IPNV strain VP2 The recombinant virus rIHNV-VP2 (Fig. 3) of gene.
The RNA of the IPNV-ChRtm213 extracted using step (3) is primer as template, the VP2-F of table 4 and VP2-R, is utilized RT-PCR single step reaction kit expands the target fragment for covering IPNV strain VP2 gene.With the pIHNV- constructed in step 63 GFP-P/M recombinant plasmid is template, and the ZT-F and ZT-R using table 4 are primer, the carrier sequence of amplification removal GFP gene.Benefit With Pfu UltraTMII Fusion HS archaeal dna polymerase, connection VP2 gene target fragment and the carrier sequence for removing GFP gene Column, construct the recombinant plasmid pIHNV-VP2 containing VP2 cDNA sequence, construction strategy is as shown in Figure 4.
The rescue of (12) recombinant virus rIHNV-VP2 strain
Take 2.0 μ g of pIHNV-VP2 plasmid, 1.0 μ g of helper plasmid pHelp-N, 0.5 pHelp-P μ g, pHelp-Nv 0.25 0.5 μ g cotransfection EPC cell of μ g and pHelp-L, concrete operation method is according to Invitrogen company 2000 transfection procedure specification of Lipofectamine carries out.Cell after transfection is placed in 15 DEG C of incubator cultures, is seen daily Cell state is examined, when CPE occurs in 60% or more cell, harvest viral suspension is placed in -80 DEG C of packing and saves backup.
The application of (13) recombinant virus rIHNV-VP2
By the recombinant virus rIHNV-VP2 injecting immune SPF rainbow trout (5 ± 1g) of harvest, every group of immune 50 tails, immunizing dose For every tail 50pfu/ tail, control group carries out inoculation using PBS.60d after immune utilizes IHNV (102Pfu/ tail) and IPNV(106Pfu/ tail) virus infect respectively, carry out immunoprotection detection.
Two, result and analysis
1, rIHNV-BLk94 strain full-length cDNA plasmid construction
The long 11132bp of IHNV-BLk94 whole genome sequence, the present invention are classified as tri- sections of genetic fragments of IH1, IH2, IH3 It is cloned, size is followed successively by 3756bp, 3680bp, 3726bp, the product after the amplification of RT-PCR single step reaction kit Electrophoretic analysis result shows that 3 sections of genetic fragment sizes are consistent with expected results (see Fig. 5).Application specific primer pair pFLC- LaSota carrier for expression of eukaryon frame sequence is expanded, and electrophoresis result shows that carrier size is consistent with expected results 3140bp (see Fig. 5).IH1, IH2, IH3 and pFLC-LaSota eukaryon table are connected according to In-Fusion PCR Cloning Kit specification Up to vector backbone segment, the plasmid pIHNV-BLk94 containing IHNV-BLk94 strain full length cDNA sequence is constructed.
2, recombinant plasmid pIHNV-GFP-N/P, pIHNV-GFP-P/M, pIHNV-GFP-M/G, pIHNV-GFP-G/NV, The building of pIHNV-GFP-NV/L
GFP N/P segment, GFP P/M segment, GFP M/G segment, GFP G/NV are expanded respectively using the primer of specificity Segment, GFP NV/L segment and pIHNV-GFP-N/P Vet carrier segments, pIHNV-GFP-P/M Vet carrier segments, PIHNV-GFP-M/G Vet carrier segments, pIHNV-GFP-G/NV Vet carrier segments, pIHNV-GFP-NV/L Vet carrier-pellet Target fragment, connect to obtain recombinant plasmid pIHNV-GFP-N/P, pIHNV-GFP-P/M, pIHNV-GFP- respectively with carrier by section It is as shown in Figure 6 to construct successful recombinant plasmid PCR qualification result by M/G, pIHNV-GFP-G/NV and pIHNV-GFP-NV/L.
3, the building of rIHNV-GFP strain eukaryon helper plasmid
Using the RNA of IHNV-BLk94 strain as template, expanded respectively using specific primer IHNV-BLk94 strain N, P, Nv and L genetic fragment, size are respectively 1176bp, 693bp, 336bp and 5961bp (see Fig. 7).Specific primer is used simultaneously Expand pFLC-LaSota vector backbone segment, according to In-Fusion PCR Cloning Kit specification respectively by N, P, Nv and L genetic fragment is connect with pFLC-LaSota vector backbone segment, constructs rescue rIHNV-GFP strain helper plasmid phelp- N, phelp-P, phelp-NV and phelp-L.
4, Revive virus rIHNV-GFP-N/P, rIHNV-GFP-P/M, rIHNV-GFP-M/G, rIHNV-GFP-G/NV and The TCID of rIHNV-GFP-NV/L50Measurement
After determining different loci insertion GFP gene, the situation of change of recombinant virus infection ability, the present invention is right respectively The TCID of each recombinant virus50It is detected.The result shows that the TCID of each Revive virus50Titre and parental virus rIHNV- BLk94 is similar, illustrates Revive virus rIHNV-GFP-N/P, rIHNV-GFP-P/M, rIHNV-GFP-M/G, rIHNV-GFP-G/ NV and rIHNV-GFP-NV/L maintains the infection ability (Fig. 8) of its parental virus.
5, Revive virus rIHNV-GFP-N/P, rIHNV-GFP-P/M, rIHNV-GFP-M/G, rIHNV-GFP-G/NV and The growth curve of rIHNV-GFP-NV/L
In order to study the duplication characteristic and its growth kinetics characteristic of Revive virus, the present invention is by viral dilution 10-5After times EPC cell is infected respectively, later every primary virus of 12h harvest, and to the TCID of different infection time point viruses50It is detected, Draw the growth curve (Fig. 9) of virus infection.As shown, each recombinant virus of expression GFP albumen is equal on same time point Even rIHNV-BLk94 parental virus maintains similar map, shows duplication similar with rIHNV-BLk94 parental virus Characteristic and growth kinetics characteristic.But the speed of growth of rIHNV-GFP-N/P is slightly compared with the recombinant virus of other expression GFP Aobvious lag about falls behind other viral 0.5-1 titres.Although rIHNV-GFP-P/M virus is slightly above on same time point RIHNV-GFP-N/P, but still it is significantly lower than other Revive virus.The titre of same time point virus is from high to low successively are as follows: rIHNV-GFP-N/P,rIHNV-GFP-P/M,rIHNV-GFP-M/G,rIHNV-GFP-G/NV,rIHNV-GFP-NV/L.This says Bright, the insertion of foreign protein GFP has a great impact for the duplication of virus, and is inserted into 3 ' ends of the gene closer to genome The duplicating efficiency of virus is influenced bigger.
6, transcriptional level detection Revive virus rIHNV-GFP-N/P, rIHNV-GFP-P/M, rIHNV-GFP-M/G, The expression quantity of rIHNV-GFP-G/NV and rIHNV-GFP-NV/L
Using specific Real-time PCR primer, using the N protein gene of virus as internal reference, in transcriptional level to each The expression quantity of Revive virus expression alien gene GFP is detected (Figure 10).The results show that each Revive virus GFP mRNA RIHNV-GFP-N/P > rIHNV-GFP-P/M > rIHNV-GFP-M/G > rIHNV-GFP-G/NV > rIHNV-GFP- is presented in expression quantity NV/L。
7, recombinant virus rIHNV-GFP-N/P, rIHNV-GFP-P/M, rIHNV-GFP-M/G, rIHNV-GFP-G/NV and The detection of rIHNV-GFP-NV/L GFP expressing quantity
Real-time PCR is the results show that foreign protein about holds the transcription amount of its mRNA to get over close to virus genomic 3 ' It is more；But the growth curve of virus but shows that foreign gene gets over the influence of the duplicating efficiency of virus closer to 3 ' ends of genome Greatly.In order to determine the optimum expression position of foreign protein, this research has carried out streaming to the GFP expressing quantity of each Revive virus Cell instrument detects (Figure 11).It can be seen from the results that the GFP expression quantity of Revive virus rIHNV-GFP-P/M is maximum, specific order For rIHNV-GFP-P/M > rIHNV-GFP-M/G > rIHNV-GFP-N/P > rIHNV-GFP-G/NV > rIHNV-GFP-NV/L.By Result above can be seen that the transcription properties for comprehensively considering IHNV genome mRNA and foreign gene to caused by virus replication It influences, foreign gene is inserted between the P gene of IHNV-BLk94 genome and M gene to the highest that can obtain foreign gene Expression quantity.
8, rIHNV-VP2 strain full-length cDNA plasmid construction and virus rescue
Using the RNA of IPNV-ChRtm213 strain as template, using primer amplified IPNV strain VP2 genetic fragment, Its size is 1329bp.Application specific primer is according to In-Fusion PCR Cloning Kit specification by VP2 gene replacement The GFP gene for falling pIHNV-GFP-P/M plasmid constructs the pIHNV-VP2 recombination matter containing IPNV strain VP2 genetic fragment Grain.After 1.0 μ g of pIHNV-VP2, pHelp-N, pHelp-P, pHelp-Nv and pHelp-L cotransfection EPC cell, save out Recombinant virus rIHNV-VP2, Cytopathic effect are as shown in figure 12.
In addition, genome sequence determination is carried out to recombinant virus rIHNV-VP2, the results show that recombinant virus rIHNV-VP2 Compared with IHNV-BLk94, difference, which is only that, to be located at the gene coding region P in IHNV-BLk94 geneome RNA (in Fig. 3 in A " P cds ") and the gene coding region M (" M CDS " in Fig. 3 in A) between A segment (" P GE-M GS " in Fig. 3 in A) replace It has been changed to segment B (" P GE-M GS-VP2gene-P GE-M GS " in Fig. 3 in B).Wherein, the sequence of the segment A is SEQ ID No.7；The sequence of the segment B is SEQ ID No.8 (i.e. SEQ ID No.7+SEQ ID No.6+SEQ ID No.7)。
9, the application of recombinant virus rIHNV-VP2
After recombinant virus rIHNV-VP2 dilution, SPF rainbow trout is immunized, the 60d after immune utilizes IHNV and IPNV virus Infection, respectively detects IPNV virus carrying capacity in the immune protective rate of IHNV and tissue.It can be seen from the results that through recombinating Viral rIHNV-VP2 immune rainbow trout (substitutes recombinant virus rIHNV- with control group in IHNV virus infection with PBS It VP2 is about) 85% (Figure 13) compared to the immune protective rate of recombinant virus；In IPNV virus infection, recombinate compared with the control group The virus load of the immunoprotection group IPNV of virus is substantially reduced (Figure 14).These results suggest that rIHNV-VP2 pairs of recombinant virus Preventing rainbow trout IHNV and IPNV virus infection has good immune protective effect, this result is the strong of China rainbow trout aquaculture Kang Fazhan provides technical guarantee.
<110>Heilongjiang Inst. of Aquatic Products, Chinese Academy of Aquatic Products Scie
<120>a kind of recombination infectious hematopoietic necrosis poison and its construction method and application
<130> GNCLN181321
<160> 8
<170> PatentIn version 3.5
<210> 1
<211> 230
<212> PRT
<213> IHNV
<400> 1
Met Ser Asp Gly Glu Gly Glu Gln Phe Phe Asp Leu Glu Gly Lys Asp
1 5 10 15
Ile Leu Arg Leu Glu Ser Arg Leu Lys Thr Pro Arg Asn Asp Gly Gln
20 25 30
Ile Asp Lys Asp Pro Arg Gln Gln Lys Gly Gly Arg Val Pro Arg Glu
35 40 45
Glu Pro Lys Lys Pro Thr Arg Arg Pro Asp Lys Asn Lys Gly Leu Ser
50 55 60
Gln Leu Glu Gln Leu Ile Leu Lys Tyr Val Glu Glu Glu Ser Cys Gln
65 70 75 80
Asp Ala Leu Lys Asp Phe Gly Gly Leu Ile Ala Asn Ile Arg Gln Ala
85 90 95
His Gln Ala Glu Met Thr Ser His Leu Glu Lys Val Ala Thr Glu His
100 105 110
Arg Ala Asn Leu Gln Ala Leu Thr Lys Ser Gln Gln Glu His Glu Lys
115 120 125
Val Ser Lys Glu Ile Leu Ser Ala Val Ile Ala Ile Arg Ser Asn Leu
130 135 140
Asn Glu Asn His Asn Pro Arg Pro Lys Pro Leu Asp Pro Asp Gln Val
145 150 155 160
Lys Ala Ala Arg Ala Leu Gly Phe Gly Ile Gly Tyr Arg Thr Ala Leu
165 170 175
Asn Val Phe Asp Arg Ile Lys Gly Val Thr Pro Asp Thr Ala Gly Ser
180 185 190
Gln Glu Val Lys Asn Met Ala Ile Arg Ala Ala Glu Asp Asp Glu Tyr
195 200 205
Glu Gly Ser Pro Thr Phe Phe Arg Arg Val Ile Asp Thr Val Lys Lys
210 215 220
Arg Met Lys Gln Gly Gln
225 230
<210> 2
<211> 195
<212> PRT
<213> IHNV
<400> 2
Met Ser Ile Phe Lys Arg Ala Lys Arg Thr Val Leu Ile Pro Pro Pro
1 5 10 15
His Leu Leu Ser Gly Asp Glu Glu Arg Val Thr Ile Leu Ser Ala Glu
20 25 30
Gly Glu Ile Lys Val Thr Gly Lys Arg Pro Thr Thr Leu Glu Glu Lys
35 40 45
Ile Tyr Tyr Ser Met Asn Leu Ala Ala Ala Ile Val Gly Gly Asp Leu
50 55 60
His Pro Ser Phe Lys Ser Met Thr Phe Leu Phe Gln Lys Glu Met Glu
65 70 75 80
Phe Gly Ser Thr Gln Glu Lys Val Asn Phe Gly Ser Arg Lys Pro Ala
85 90 95
Pro Gln Thr Thr Tyr Gln Val Met Lys Ala Arg Glu Val Tyr Leu Gln
100 105 110
Thr Gln Pro Leu Glu Lys Lys Ile Pro Met Gln Thr Tyr Ser Val Ser
115 120 125
Thr Glu Gly Ala Thr Ile Asn Phe Thr Gly Arg Phe Leu Phe Ser Ser
130 135 140
Ser His Val Gly Cys Asp Asp Asn Arg Thr Lys Leu Ala Gly Leu Asp
145 150 155 160
Gly Phe Thr Thr Ser Asn Ser Tyr Gln Arg Val Lys Asp Tyr Tyr Ala
165 170 175
Gln Glu Thr Ala Leu Ala Leu Thr Phe Ala Ala Pro Glu Lys Arg Gly
180 185 190
Lys Glu Lys
195
<210> 3
<211> 442
<212> PRT
<213> IPNV
<400> 3
Met Asn Thr Ser Lys Ala Thr Ala Thr Tyr Leu Arg Ser Ile Met Leu
1 5 10 15
Pro Glu Asn Gly Pro Ala Ser Ile Pro Asp Asp Ile Thr Glu Arg His
20 25 30
Ile Leu Lys Gln Glu Thr Ser Ser Tyr Asn Leu Glu Val Ser Glu Ser
35 40 45
Gly Ser Gly Leu Leu Val Cys Phe Pro Gly Ala Pro Gly Ser Arg Val
50 55 60
Gly Ala His Tyr Arg Trp Asn Gln Asn Gln Thr Ala Leu Glu Phe Asp
65 70 75 80
Gln Trp Leu Glu Thr Ser Gln Asp Leu Lys Lys Ala Phe Asn Tyr Gly
85 90 95
Arg Leu Ile Ser Arg Lys Tyr Asp Ile Gln Ser Ser Thr Leu Pro Ala
100 105 110
Gly Leu Tyr Ala Leu Asn Gly Thr Leu Asn Ala Ala Thr Phe Glu Gly
115 120 125
Ser Leu Ser Glu Val Glu Asn Leu Thr Tyr Asn Ser Leu Met Ser Leu
130 135 140
Thr Thr Asn Pro Gln Asp Lys Val Asn Asn Gln Ile Val Thr Lys Gly
145 150 155 160
Ile Thr Val Leu Asn Leu Pro Thr Gly Phe Asp Lys Pro Tyr Val Arg
165 170 175
Leu Glu Asp Glu Thr Pro Gln Gly Pro Gln Ser Met Asn Gly Ala Arg
180 185 190
Met Arg Cys Thr Ala Ala Ile Ala Pro Arg Arg Tyr Glu Ile Asp Leu
195 200 205
Pro Ser Glu Arg Leu Pro Thr Val Ala Ala Thr Gly Ala Pro Thr Thr
210 215 220
Ile Tyr Glu Gly Asn Ala Asp Ile Val Asn Ser Thr Thr Val Thr Gly
225 230 235 240
Asp Ile Thr Phe Gln Leu Glu Asn Glu Pro Ala Asn Glu Thr Thr Phe
245 250 255
Asp Phe Ile Leu Gln Phe Leu Gly Leu Asp Asn Asp Val Pro Val Val
260 265 270
Thr Val Thr Ser Ser Thr Leu Val Thr Val Glu Asn His Arg Gly Ala
275 280 285
Ser Ala Lys Phe Thr Gln Ser Ile Pro Thr Glu Met Ile Thr Lys Pro
290 295 300
Ile Thr Arg Val Lys Leu Ala Tyr Lys Leu Asn Gln Gln Thr Ala Ile
305 310 315 320
Glu Asn Pro Ala Thr Leu Gly Ala Met Gly Pro Ala Ser Val Ser Phe
325 330 335
Ser Ser Gly Asn Gly Asn Val Pro Gly Val Leu Arg Pro Ile Thr Leu
340 345 350
Val Ala Tyr Glu Lys Met Thr Pro Gln Ser Ile Leu Thr Val Ala Gly
355 360 365
Val Ser Asn Tyr Glu Leu Ile Pro Asn Pro Asp Leu Leu Lys Asn Met
370 375 380
Val Thr Lys Tyr Gly Lys Tyr Asp Pro Glu Gly Leu Asn Tyr Ala Lys
385 390 395 400
Met Ile Leu Ser His Arg Glu Glu Leu Asp Ile Arg Thr Val Trp Arg
405 410 415
Thr Glu Glu Tyr Lys Glu Arg Thr Arg Ala Phe Lys Glu Ile Thr Asp
420 425 430
Phe Thr Ser Asp Leu Pro Thr Ser Lys Ala
435 440
<210> 4
<211> 693
<212> RNA
<213> IHNV
<400> 4
augucagaug gagaaggaga acaguucuuc gaucuagaag gcaaagacau acugaggcua 60
gaaucccgcu ugaaaacccc gcggaaugac gggcaaauag acaaggaccc cagacaacag 120
aaggggggcc gggugccucg agaggaacca aagaaaccca ccaggagacc cgacaagaac 180
aaggguuuau cccaacugga gcaacuaauc cuaaaauacg uugaggagga gagcugucag 240
gaugcccuga aggacuucgg aggucuaaua gcuaacauca gacaggccca ccaggccgaa 300
augacaucuc acuuagaaaa gguugccacg gagcaccgag ccaaccuuca ggcucuuaca 360
aagucccagc aagagcacga gaaagucucg aaggagauuu ugucugcggu aauugcuauu 420
cgauccaacc ucaacgagaa ccacaauccc cggcccaagc cacucgaccc ggaucaggug 480
aaggccgcuc gugcccuugg auucggaauu ggguaucgaa cggcccucaa ugucuucgac 540
cgaaucaagg gagucacccc agacaccgca ggaucccaag aggugaagaa cauggccauu 600
cgggcggcgg aggaugauga auacgagggg agucccacuu ucuucaggag ggugauagac 660
accgugaaga agcgcaugaa gcagggucaa uag 693
<210> 5
<211> 588
<212> RNA
<213> IHNV
<400> 5
auguccauuu ucaagagagc aaagagaaca guucugaucc cuccuccuca ccuccucagc 60
ggagacgagg agagggugac aauacucagu gcagaggggg agaucaaggu gacuggaaaa 120
agaccaacca cacuugagga gaagaucuau uacucuauga aucuggcggc ugccaucgua 180
gggggagauc uacaccccuc auucaaaucc augaccuuuc uguuucagaa agagauggag 240
uucggaagca cccaagaaaa agucaacuuc gggucuagga aacccgcacc ucagaccacc 300
uaccagguga ugaaggcgag ggaggucuac cuucagaccc agccucucga gaagaagauc 360
ccaaugcaga ccuacucagu cagcacagag ggggcuacca ucaacuucac aggacgguuc 420
cuguuuucau ccagccaugu aggcugugac gacaacagga ccaaacuggc ggggcuugau 480
ggguucacaa ccuccaacag cuaccagagg gucaaagacu acuaugccca ggagacagcc 540
cuggcccuga ccuucgccgc ucccgaaaaa cgggggaagg aaaaauag 588
<210> 6
<211> 1329
<212> RNA
<213> IPNV
<400> 6
augaacacau ccaaggcaac cgcaacuuac uugagaucca uuaugcuucc cgagaauggg 60
ccagcaagca uuccggacga cauaacagag aggcauauac uaaaacaaga gaccucguca 120
uauaacuuag aggucucuga aucaggaagu gggcuucuug ucugcuuccc uggggcuccu 180
ggauccagag ucggugccca cuacaggugg aaucagaacc agacggcacu agaauucgac 240
caguggcuag agacgucaca ggaccuaaag aaggcauuca acuacgggag acugaucuca 300
cggaaauaug acauccagag cucaacccuc cccgcugguc uguaugcacu caaugggacc 360
cuaaacgccg ccaccuucga gggaagucug ucugaaguag agaaccuaac cuacaacagc 420
cugauguccc uaacaacaaa cccacaggac aaggucaaca aucaaauagu gaccaaagga 480
auuaccgucc ugaaucuacc aacuggguuu gacaagccau acguccgccu agaggacgag 540
acgccacagg gcccccaguc caugaacgga gcaaggauga ggugcacagc ugccaucgcg 600
ccaaggaggu augaaaucga ccucccaucc gaacgacugc cgaccguagc cgcgacuggg 660
gccccaacaa caaucuacga ggggaaugcu gacaucguaa acuccacaac agugaccggu 720
gacauaacau uccagcucga gaacgaaccu gccaacgaga caacguuuga cuucauucua 780
caguuccugg ggcuggacaa cgacgucccc guggucaccg ugacaagcuc cacgcugguc 840
acgguggaaa accacagggg ggcgucagcc aaguucaccc agucaauucc aacagagaug 900
aucaccaaac caauuacacg ggucaaacug gccuacaagc ucaaccagca gaccgcaauc 960
gagaacccag caacgcuugg agccaugggg ccggcaucgg ucucauucuc cuccgggaac 1020
ggcaaugugc cggggguccu aagacccaua acccuagugg cguacgagaa gaugaccccc 1080
cagucaaucc ugaccguggc uggcguaucc aacuaugagc ugaucccaaa cccagaccua 1140
cugaagaaca uggucaccaa guauggaaag uaugacccug agggccuuaa cuaugccaag 1200
augauccugu cccacagaga ggagcuggac aucagaaccg ucuggaggac ugaggaauac 1260
aaagaaagga caagagcauu caaagagauc acugacuuca caagugaccu accaaccuca 1320
aaggcauga 1329
<210> 7
<211> 96
<212> RNA
<213> IHNV
<400> 7
acauccuccu ccgggccccc gguuaccaag acagaaaaaa auggcacgca aguguaucgu 60
uccaaacgaa guccaagagu caguucaaac gagagc 96
<210> 8
<211> 1521
<212> RNA
<213> Artificial sequence
<400> 8
acauccuccu ccgggccccc gguuaccaag acagaaaaaa auggcacgca aguguaucgu 60
uccaaacgaa guccaagagu caguucaaac gagagcauga acacauccaa ggcaaccgca 120
acuuacuuga gauccauuau gcuucccgag aaugggccag caagcauucc ggacgacaua 180
acagagaggc auauacuaaa acaagagacc ucgucauaua acuuagaggu cucugaauca 240
ggaagugggc uucuugucug cuucccuggg gcuccuggau ccagagucgg ugcccacuac 300
agguggaauc agaaccagac ggcacuagaa uucgaccagu ggcuagagac gucacaggac 360
cuaaagaagg cauucaacua cgggagacug aucucacgga aauaugacau ccagagcuca 420
acccuccccg cuggucugua ugcacucaau gggacccuaa acgccgccac cuucgaggga 480
agucugucug aaguagagaa ccuaaccuac aacagccuga ugucccuaac aacaaaccca 540
caggacaagg ucaacaauca aauagugacc aaaggaauua ccguccugaa ucuaccaacu 600
ggguuugaca agccauacgu ccgccuagag gacgagacgc cacagggccc ccaguccaug 660
aacggagcaa ggaugaggug cacagcugcc aucgcgccaa ggagguauga aaucgaccuc 720
ccauccgaac gacugccgac cguagccgcg acuggggccc caacaacaau cuacgagggg 780
aaugcugaca ucguaaacuc cacaacagug accggugaca uaacauucca gcucgagaac 840
gaaccugcca acgagacaac guuugacuuc auucuacagu uccuggggcu ggacaacgac 900
guccccgugg ucaccgugac aagcuccacg cuggucacgg uggaaaacca caggggggcg 960
ucagccaagu ucacccaguc aauuccaaca gagaugauca ccaaaccaau uacacggguc 1020
aaacuggccu acaagcucaa ccagcagacc gcaaucgaga acccagcaac gcuuggagcc 1080
auggggccgg caucggucuc auucuccucc gggaacggca augugccggg gguccuaaga 1140
cccauaaccc uaguggcgua cgagaagaug accccccagu caauccugac cguggcuggc 1200
guauccaacu augagcugau cccaaaccca gaccuacuga agaacauggu caccaaguau 1260
ggaaaguaug acccugaggg ccuuaacuau gccaagauga uccuguccca cagagaggag 1320
cuggacauca gaaccgucug gaggacugag gaauacaaag aaaggacaag agcauucaaa 1380
gagaucacug acuucacaag ugaccuacca accucaaagg caugaacauc cuccuccggg 1440
cccccgguua ccaagacaga aaaaaauggc acgcaagugu aucguuccaa acgaagucca 1500
agagucaguu caaacgagag c 1521

Claims (10)

1. recombinate infectious hematopoietic necrosis poison, it is characterised in that: the recombination infectious hematopoietic necrosis poison and Infectious hematopoietic necrosis's poison before transformation is compared, and difference is only that the infectious hematopoietic organ necrosis before the transformation Also containing the encoding gene of destination protein between P gene and M gene in the geneome RNA of virus.
2. recombination infectious hematopoietic necrosis poison according to claim 1, it is characterised in that: the destination protein Encoding gene is the antigen gene of target viral or the encoding gene of labelled protein；
Further, the antigen gene of the target viral is the VP2 gene of infectious pancreas necrosis virus；The labelled protein For green fluorescent protein；
Further, the infectious pancreas necrosis virus is infectious pancreas necrosis virus ChRtm213 plants.
3. recombination infectious hematopoietic necrosis poison according to claim 1 or 2, it is characterised in that: before the transformation Infectious hematopoietic necrosis's poison geneome RNA in the P gene coding SEQ ID No.1 shown in phosphoprotein； And/or
The M gene in the geneome RNA of infectious hematopoietic necrosis's poison before the transformation encodes SEQ ID No.2 Shown in stromatin；And/or
VP2 albumen shown in the VP2 gene coding SEQ ID No.3 of the infectious pancreas necrosis virus.
4. recombination infectious hematopoietic necrosis poison according to claim 3, it is characterised in that: the biography before the transformation The nucleotide sequence such as SEQ ID No.4 of the code area of the P gene in the geneome RNA of metachromia hematopoietic necrosis virus It is shown；And/or
The nucleosides of the code area of the M gene in the geneome RNA of infectious hematopoietic necrosis's poison before the transformation Acid sequence is as shown in SEQ ID No.5；And/or
The nucleotide sequence of the code area of the VP2 gene of the infectious pancreas necrosis virus is as shown in SEQ ID No.6.
5. recombination infectious hematopoietic necrosis poison according to any one of claims 1-4, it is characterised in that: described heavy Group infectious hematopoietic necrosis's poison compared with infectious hematopoietic necrosis's poison before the transformation, difference be only that by Positioned at the code area of the P gene and the M base in the geneome RNA of infectious hematopoietic necrosis's poison before the transformation A segment between the code area of cause is replaced for segment B；The sequence of the segment A is SEQ ID No.7；The sequence of the segment B It is classified as SEQ ID No.8.
6. any recombination infectious hematopoietic necrosis's poison in -5 according to claim 1, it is characterised in that: described heavy Group infectious hematopoietic necrosis's poison is prepared according to claim 7 or 8 the methods.
7. a kind of method for preparing recombination infectious hematopoietic necrosis's poison as claimed in any one of claims 1 to 5, including such as Lower step: by the recombination matter of the corresponding cDNA sequence of geneome RNA containing recombination infectious hematopoietic necrosis's poison Grain and helper plasmid cotransfection EPC cell, to obtain the recombination infectious hematopoietic necrosis poison.
8. according to the method described in claim 7, it is characterized by: described " contain the recombination infectious hematopoietic organ necrosis The starting recombination infectious hematopoietic necrosis poison in the recombinant plasmid of the corresponding cDNA sequence of geneome RNA of virus " The promoter of geneome RNA corresponding cDNA sequence expression be T7 promoter；
And/or
The helper plasmid shares 4: N in the geneome RNA containing infectious hematopoietic necrosis's poison before the transformation The helper plasmid 1 of the corresponding cDNA sequence in the code area of gene；Contain infectious hematopoietic necrosis's poison before the transformation Geneome RNA in P gene the corresponding cDNA sequence in code area helper plasmid 2；It is made containing the infectiousness before the transformation The helper plasmid 3 of the corresponding cDNA sequence in code area of NV gene in the geneome RNA of blood organ necrosis virus；Change containing described The auxiliary matter of the corresponding cDNA sequence in code area of L gene in the geneome RNA of infectious hematopoietic necrosis's poison before making Grain 4.
The biomaterial of following 9. (a1) or (a2) or (a3):
(a1) containing it is as claimed in any one of claims 1 to 6 recombination infectious hematopoietic necrosis's poison in vitro zooblast or Recombinant bacterium；
(a2) containing it is as claimed in any one of claims 1 to 6 recombination infectious hematopoietic necrosis's poison geneome RNA or The carrier of cDNA；
(a3) vaccine containing recombination infectious hematopoietic necrosis's poison as claimed in any one of claims 1 to 6.
10. following any application:
(b1) recombination infectious hematopoietic necrosis poison as claimed in any one of claims 1 to 6 or life as claimed in claim 9 Object material is in preparation for preventing and/or treating since infectious hematopoietic necrosis is malicious and/or as stated in claim 2 Target viral infects the application in the product of associated diseases；
(b2) recombination infectious hematopoietic necrosis poison as claimed in any one of claims 1 to 6 or life as claimed in claim 9 Object material is in preparation for inhibiting infectious hematopoietic necrosis's poison and/or target viral as stated in claim 2 infection Product in application；
(b3) recombination infectious hematopoietic necrosis poison as claimed in any one of claims 1 to 6 or life as claimed in claim 9 Object material is preventing and/or is treating due to infectious hematopoietic necrosis's poison and/or target viral as stated in claim 2 Infect the application in associated diseases；
(b4) recombination infectious hematopoietic necrosis poison as claimed in any one of claims 1 to 6 or life as claimed in claim 9 Object material is inhibiting the application in infectious hematopoietic necrosis's poison and/or target viral as stated in claim 2 infection；
Further, the target viral is infectious pancreas necrosis virus.
CN201811100029.1A 2018-09-20 2018-09-20 Recombinant infectious hematopoietic necrosis virus and construction method and application thereof Active CN109136200B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811100029.1A CN109136200B (en) 2018-09-20 2018-09-20 Recombinant infectious hematopoietic necrosis virus and construction method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811100029.1A CN109136200B (en) 2018-09-20 2018-09-20 Recombinant infectious hematopoietic necrosis virus and construction method and application thereof

Publications (2)

Publication Number Publication Date
CN109136200A true CN109136200A (en) 2019-01-04
CN109136200B CN109136200B (en) 2022-02-18

Family

ID=64815305

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811100029.1A Active CN109136200B (en) 2018-09-20 2018-09-20 Recombinant infectious hematopoietic necrosis virus and construction method and application thereof

Country Status (1)

Country Link
CN (1) CN109136200B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112852873A (en) * 2021-02-04 2021-05-28 华中农业大学 Construction method of porcine delta coronavirus infectious clone plasmid
CN113122510A (en) * 2021-04-12 2021-07-16 中国水产科学研究院黑龙江水产研究所 Infectious hematopoietic necrosis vaccine and method for amplifying virus thereof on phoxinus fatigani muscle cells
CN115887638A (en) * 2022-06-16 2023-04-04 中国水产科学研究院东海水产研究所 Processing method of recombinant adenovirus vaccine for infectious hematopoietic necrosis and infectious pancreatic necrosis of salmonidae fishes

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1121959A (en) * 1994-07-18 1996-05-08 阿克佐诺贝尔公司 Recombinant infectious non-segmented negative strand RNA virus
WO2002036618A1 (en) * 2000-11-04 2002-05-10 Rna Inc. Novel genes encoding g and m1 proteins of a korean isolate ihnv-scs and a vaccine therefrom against infectious hematopoietic necrosis virus in salmonid fish
KR20030078807A (en) * 2002-03-30 2003-10-08 주식회사 알엔에이 Development of complex DNA and protein vaccines against infectious virus in aquaculture salmon, and optimizing of vaccine treatment
EP1440086A1 (en) * 2001-10-19 2004-07-28 Akzo Nobel N.V. Infectious salmon anaemia virus vaccine
CN1681530A (en) * 2002-09-17 2005-10-12 诺瓦提斯公司 IHNV G protein for immune stimulation
CN1738903A (en) * 2002-12-13 2006-02-22 诺瓦提斯公司 Immunization of fish with plant-expressed recombinant proteins
CN101421294A (en) * 2006-03-15 2009-04-29 英特威国际有限公司 Recombinant newcastle disease virus expressing H5 hemagglutinin of avian influenza virus
CN101508969A (en) * 2009-01-14 2009-08-19 东北农业大学 Recombinant lactobacillus casei for expressing infectivity pancreatic necrosis virus VP2 protein and production method thereof
EP2658866A1 (en) * 2010-12-29 2013-11-06 Intervet International B.V. Salmonid alphavirus protein e2
EP2906704A1 (en) * 2012-10-15 2015-08-19 Institut National De La Recherche Agronomique (INRA) Recombinant novirhabdovirus usable as an antigen vector
CN104884084A (en) * 2012-09-26 2015-09-02 Fvg有限公司 Subunit immersion vaccines for fish
CN104911152A (en) * 2015-06-08 2015-09-16 东北农业大学 Recombination infectious haematopoietic necrosis virus (rIHNV HLJ-09) strain and construction method and application thereof
CN105816871A (en) * 2016-05-12 2016-08-03 中国水产科学研究院黑龙江水产研究所 Infectious hematopoietic necrosis (IHN) nucleic acid vaccines for Chinese rainbow trout and application thereof
CN105861450A (en) * 2016-05-12 2016-08-17 中国水产科学研究院黑龙江水产研究所 Nucleic acid vaccine for infectious hemopoietic necrosis of Chinese rainbow trouts and application of nucleic acid vaccine
CN106890327A (en) * 2017-02-28 2017-06-27 兰州威特森生物科技有限公司 A kind of live vector vaccine for preventing and treating rainbow trout infectious hematopoietic organ necrosis disease and its preparation method and application

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1121959A (en) * 1994-07-18 1996-05-08 阿克佐诺贝尔公司 Recombinant infectious non-segmented negative strand RNA virus
WO2002036618A1 (en) * 2000-11-04 2002-05-10 Rna Inc. Novel genes encoding g and m1 proteins of a korean isolate ihnv-scs and a vaccine therefrom against infectious hematopoietic necrosis virus in salmonid fish
EP1440086A1 (en) * 2001-10-19 2004-07-28 Akzo Nobel N.V. Infectious salmon anaemia virus vaccine
KR20030078807A (en) * 2002-03-30 2003-10-08 주식회사 알엔에이 Development of complex DNA and protein vaccines against infectious virus in aquaculture salmon, and optimizing of vaccine treatment
CN1681530A (en) * 2002-09-17 2005-10-12 诺瓦提斯公司 IHNV G protein for immune stimulation
CN1738903A (en) * 2002-12-13 2006-02-22 诺瓦提斯公司 Immunization of fish with plant-expressed recombinant proteins
CN101421294A (en) * 2006-03-15 2009-04-29 英特威国际有限公司 Recombinant newcastle disease virus expressing H5 hemagglutinin of avian influenza virus
CN101508969A (en) * 2009-01-14 2009-08-19 东北农业大学 Recombinant lactobacillus casei for expressing infectivity pancreatic necrosis virus VP2 protein and production method thereof
EP2658866A1 (en) * 2010-12-29 2013-11-06 Intervet International B.V. Salmonid alphavirus protein e2
CN104884084A (en) * 2012-09-26 2015-09-02 Fvg有限公司 Subunit immersion vaccines for fish
EP2906704A1 (en) * 2012-10-15 2015-08-19 Institut National De La Recherche Agronomique (INRA) Recombinant novirhabdovirus usable as an antigen vector
CN104911152A (en) * 2015-06-08 2015-09-16 东北农业大学 Recombination infectious haematopoietic necrosis virus (rIHNV HLJ-09) strain and construction method and application thereof
CN105816871A (en) * 2016-05-12 2016-08-03 中国水产科学研究院黑龙江水产研究所 Infectious hematopoietic necrosis (IHN) nucleic acid vaccines for Chinese rainbow trout and application thereof
CN105861450A (en) * 2016-05-12 2016-08-17 中国水产科学研究院黑龙江水产研究所 Nucleic acid vaccine for infectious hemopoietic necrosis of Chinese rainbow trouts and application of nucleic acid vaccine
CN106890327A (en) * 2017-02-28 2017-06-27 兰州威特森生物科技有限公司 A kind of live vector vaccine for preventing and treating rainbow trout infectious hematopoietic organ necrosis disease and its preparation method and application

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JI,F.等: "Infectious pancreatic necrosis virus isolate ChRtm213 segment A, complete sequence", 《GENBANK》 *
JING‑ZHUANG ZHAO等: "Identifcation of the optimal insertion site for expression of a foreign gene in an infectious hematopoietic necrosis virus vector", 《ARCHIVES OF VIROLOGY》 *
JING-ZHUANGZHAO等: "A chimeric recombinant infectious hematopoietic necrosis virus induces protective immune responses against infectious hematopoietic necrosis and infectious pancreatic necrosis in rainbow trout", 《MOLECULAR IMMUNOLOGY》 *
MENGTINGGUO等: "Recombinant infectious hematopoietic necrosis virus expressing infectious pancreatic necrosis virus VP2 protein induces immunity against both pathogens", 《FISH & SHELLFISH IMMUNOLOGY》 *
代静等: "传染性造血器官坏死病病毒的重组及安全效价分析", 《中国兽医杂志》 *
吉尚雷等: "传染性造血器官坏死病病毒CJ-13株糖蛋白的原核表达及免疫原性", 《西北农林科技大学学报(自然科学版)》 *
李渊等: "传染性造血器官坏死病核酸疫苗的构建及其抗性基因对环境细菌抗性的影响", 《中国水产科学》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112852873A (en) * 2021-02-04 2021-05-28 华中农业大学 Construction method of porcine delta coronavirus infectious clone plasmid
CN113122510A (en) * 2021-04-12 2021-07-16 中国水产科学研究院黑龙江水产研究所 Infectious hematopoietic necrosis vaccine and method for amplifying virus thereof on phoxinus fatigani muscle cells
CN115887638A (en) * 2022-06-16 2023-04-04 中国水产科学研究院东海水产研究所 Processing method of recombinant adenovirus vaccine for infectious hematopoietic necrosis and infectious pancreatic necrosis of salmonidae fishes

Also Published As

Publication number Publication date
CN109136200B (en) 2022-02-18

Similar Documents

Publication Publication Date Title
JP5508252B2 (en) Recombinant turkey herpesvirus containing avian influenza gene
CN104918952B (en) Express recombinant measles virus and its application of chikungunya virus polypeptide
CN111575247B (en) Newcastle disease chimeric virus marked vaccine strain and construction method and application thereof
JP5908948B2 (en) Method for producing virus strain for vaccine of reoviridae virus
US20190203170A1 (en) Avian Cells for Improved Virus Production
WO2020258757A1 (en) Mutant strain of type 3 duck hepatovirus ch-p60-117c strain and construction method therefor
CN110218706B (en) Construction and application of recombinant turkey herpesvirus expressing HA protein of H7N9 subtype highly pathogenic avian influenza virus
CN104195116B (en) A kind of recombinant Newcastle disease virus and its construction method for expressing goose parvovirus VP3 genes
CN109136200A (en) A kind of recombination infectious hematopoietic necrosis poison and its construction method and application
CN104962581A (en) Recombined new castle disease virus vaccine strain for expressing African swine fever virus p72 proteins
CN109321534A (en) A kind of recombination VIII type newcastle disease virus low virulent strain
CN109321535A (en) A kind of heat-staple newcastle disease virus attenuated vaccine Candidate Strain
CN101586120B (en) Rabies virus Flury-LEP vaccine strain reverse genetic operating system and LEP green fluorescent protein recombination viral vector
CN109468325A (en) Influence PRRSV duplication and SRP14 gene and its application of proliferation
CN106399267A (en) Recombinant turkey herpesvirus virus strain rHOH expressing H7N9 subtype avian influenza virus haemagglutinin protein and construction method
CN106916832B (en) O-type foot-and-mouth disease virus recombinant nucleic acid, recombinant vaccine strain, preparation method and application thereof
CN113337476B (en) Foot-and-mouth disease O-type PanASia-2 pedigree reserve vaccine strain, construction method and application thereof
ES2795040T3 (en) Methods to produce viruses
CN110904056B (en) Infectious bronchitis virus rH120-YZS1 delta 5a and construction method and application thereof
CN114107226A (en) Recombinant avian adenovirus type 4 live vector vaccine strain for expressing vvIBDV-VP2 protein, and construction method and application thereof
CN103589693B (en) A kind of expression IBDV VP2 and bursa of Fabricius bursin chimeric protein recombinant herpesvirus of turkeys
CN109234315A (en) A kind of recombinant herpesvirus of turkeys strain for expressing infectious bursal disease virus VP 2 gene
CN104357460A (en) Recombinant duck viral enteritis virus, preparation method and applications
CN113897376B (en) HN protein mutated gene VII type Newcastle disease virus recombinant vaccine strain
CN116814563A (en) Duck enteritis virus strain and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant